Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Biovertis AG
DescriptionWater-soluble, IV prodrug of MCB3681, a small molecule quinolonyl-oxazolidinone antibiotic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI)
Regulatory Designation U.S. - Fast Track (Treat Clostridium difficile infection (CDI));
U.S. - Qualified Infectious Disease Program (Treat Clostridium difficile infection (CDI))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today